Amanda Paris
Adult Health · Coral Springs, FLNPI 1942659792
Payments from drug & device makers
Across 168 payments — averaging $21.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$1K
- Boehringer Ingelheim$482
- Merz North America, Inc.$115
- Mylan Specialty L.p.$113
- Sanofi$65
- plus $207 from 8 others
What the payments were for
- Food & beverage$3,645100%
- Education$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 60 | $1,343 |
| GSK | 57 | $1,337 |
| Boehringer Ingelheim | 33 | $482 |
| Merz North America, Inc. | 1 | $115 |
| Mylan Specialty L.p. | 5 | $113 |
| Sanofi | 3 | $65 |
| Amgen | 1 | $48 |
| Advanced Respiratory, Inc | 1 | $38 |
| Actelion Pharmaceuticals US, Inc. | 1 | $23 |
| Inogen, Inc. | 1 | $22 |
| Genentech USA, Inc. | 2 | $21 |
| Sunovion Pharmaceuticals Inc. | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Gilead | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,661 in reported general payments places this provider in the 85th percentile of 2,237 adult health providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 59 | $42,784 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 29 | $21,264 |
| Breo ElliptaFluticasone/Vilanterol | 38 | $19,852 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 27 | $14,616 |
| SymbicortBudesonide/Formoterol Fumarate | 34 | $13,338 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 17 | $9,862 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 20 | $4,749 |
| Wixela InhubFluticasone Propion/Salmeterol | 41 | $3,555 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 109 | $3,026 |
| Montelukast Sodium | 225 | $1,494 |
| Ventolin HfaAlbuterol Sulfate | 25 | $1,172 |
| Fluticasone Propionate | 60 | $749 |
| Omeprazole | 12 | $106 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $1,337 | $72,497114 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,343 | $34,60263 claims |
| Boehringer IngelheimStiolto Respimat | $482 | $14,61627 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,237 adult health providers in Florida.
Other adult health in Coral Springs
- Patricia PagnottaMaitland$441K
- Carly KoelschSarasota$265K
- Norma SolisMiami$150K
- Ashley PontenbergWinter Park$136K
- Jeffrey HernandezMiami$122K
- Jamie JohnsonTampa$58K
- Jessica MangesClearwater$52K
- Sita SwamyOrlando$49K
- Alejandro Dela CruzOrlando$44K
- Cynthia OteroMaitland$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.